Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Walgreens Boots Alliance Inc. WBA, -1.92% said late Wednesday its board has declared a quarterly dividend of 48 cents a share, an increase of 0.5%. The dividend is payable on Sept.

Walgreens Boots Alliance raises dividend

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 48 cents per share.

Walgreens Boots Alliance Increases Quarterly Dividend

It's not exactly a safe harbor from the bear market, but it could be a better option than growth stocks.

2 Reasons to Buy Walgreens Stock, and 1 Reason to Sell

A few warning lights are flashing, but new growth initiatives are already bearing fruit.

3 Things About Walgreens That Smart Investors Know

Amcor Plc

Franklin Resources

Leggett & Platt

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. The 65 Aristocrats screened as of July 5, 2022, represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 23.2%-41.21% topped by CAT & SWK.

Buy 4 July S&P 500 Dividend Aristocrats Out Of 65

Why Walgreens Q3 Earnings Weren't Bad

Home Depot

Target

These three retailers are trading at historically low P/E ratios.

Why Home Depot, Target, and Walgreens Stocks Have Trailed the Market This Year

The pharmacy chain's future plans were upset by global economic conditions.

Why Walgreens Boots Alliance Tumbled 13.5% in June

Walgreens' adjusted earnings declining 10% to $5.40 over the last twelve months, compared to $5.99 in 2019.

Should You Buy Walgreens Stock At $40?

Salesforce

Chevron

The Dow Jones Industrial Average is home to three incredible deals.

3 Dow Stocks That Are Screaming Buys in July

General Mills

Coca-Cola

Mondelez

Walmart

Should investors invest in these consumer staples stocks amid recession concerns?

Good Stocks To Buy Now? 5 Consumer Staples Stocks To Know

Zacks.com users have recently been watching Walgreens (WBA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Most-Watched Stock Walgreens Boots Alliance, Inc. (WBA) Worth Betting on Now?

Walgreens is on track to open 100 Health Corners by the end of the year as part of the drugstore chain's effort to help health plan subscribers better manage chronic conditions.

Walgreens On Track To Open 100 ‘Health Corners' By Year's End

CVS Health

Many income investors are drawn to healthcare stocks like CVS and Walgreens for their stable dividends. Indeed, both stocks have demonstrated long-term dividend consistency and growth, and Walgreens is a dividend champion with 46 years of consecutive raises.

CVS Vs. Walgreens: Which Is The Better Dividend Stock?

In trading on Thursday, shares of Walgreens Boots Alliance were yielding above the 5% mark based on its quarterly dividend (annualized to $1.91)

Walgreens Boots Alliance Shares Cross 5% Yield Mark

Walgreens Boots (WBA) reports better-than-expected Q3 earnings, with robust sales contributions from the International and Walgreens Health segments.

Walgreens Boots (WBA) Q3 Earnings Top Estimates, Revenues Miss

AT&T

TC Energy

Walgreens, TC Energy, and AT&T have all been making regular dividend payments for a long time.

Want to Make $400 a Month in Dividends? Invest in These 3 Stocks

What pandemic? With COVID-19 vaccinations and urgent care visits dropping through spring as infection fears faded, Big Pharmacy is looking to get back on track with expansion plans, a recovery in prescriptions and wellness sales products, and more access to primary care via the growing networks of retail primary care clinics being pursued by major […]

Walgreens Looks to Primary Care and Virtual for Growth, as Do Rivals

Walgreens Boots Alliance, Inc. (NASDAQ:WBA ) Q3 2022 Earnings Conference Call June 30, 2022 8:30 AM ET Company Participants Tiffany Kanaga - Vice President, Global Investor Relations Rosalind Brewer - Chief Executive Officer James Kehoe - Executive Vice President and Global Chief Financial Officer John Standley - President, Walgreens Conference Call Participants Lisa Gill - JPMorgan George Hill - Deutsche Bank Michael Cherny - Bank of America Elizabeth Anderson - Evercore ISI Steven Valiquette - Barclays Operator Good morning. My name is Chris, and I'll be your conference operator today.

Walgreens Boots Alliance, Inc. (WBA) CEO Rosalind Brewer on Q3 2022 Results - Earnings Call Transcript

Walgreens Boots Alliance (NASDAQ: WBA) is one of our top picks for long-term oriented high-yield investors because of the turnaround story. The company has been working to realign itself for growth over the past few years and those efforts are working.

The Value Of High-Yielding Walgreens Boots Alliance Deepens

Walgreens Boots Alliance Inc (NASDAQ: WBA) on Thursday said lower demand for COVID vaccine and tests resulted in a significant year-on-year hit to its third-quarter results. Shares are down more than 3.0% this morning.

Walgreens stock down despite market-beating Q3 results

Walgreens (WBA) stock is falling on Thursday following the release of the company's earnings report for its fiscal third quarter of 2022. The post Walgreens (WBA) Stock Slides Following Q3 Earnings Report appeared first on InvestorPlace.

Walgreens (WBA) Stock Slides Following Q3 Earnings Report

Walgreens wants to double the number of prescriptions being filled by its robot-powered micro fulfillment centers, the pharmacy chain's chief executive said Thursday (June 30). Speaking on a conference call to announce third quarter 2022 earnings results, Walgreens Boots Alliance CEO Rosalind Brewer said those centers, first launched earlier this year, now fill about 20% […]

Walgreens Plans to Double Robot Pharmacy Use

Walgreens (WBA) delivered earnings and revenue surprises of 1.05% and 0.43%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Walgreens Boots Alliance (WBA) Beats Q3 Earnings Estimates

Walgreens Boots Alliance Inc's (NASDAQ: WBA) Q3 FY22 sales decreased 4.2% Y/Y to $32.6 billion, down 2.8% on a constant currency basis, beating the consensus of $32.06 billion. Adjusted EPS reached $0.96, beating the consensus of $0.92, down 28.9% on a constant currency basis against.

News for Walgreens Stock (WBA)